Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells

Seshu Vardhan, Suban K. Sahoo*

Department of Chemistry, Sardar Vallabhbhai National Institute of Technology (SVNIT), Surat, 395007, Gujarat, India

**Article info**

**Article history:**
Received 12 February 2021
Received in revised form 31 March 2021
Accepted 6 April 2021
Available online 12 April 2021

**Keywords:**
COVID-19
SARS-CoV-2
Protein-protein docking
Phytochemicals
Drugs

**Abstract**

**Background and aim:** The year 2020 begins with the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that cause the disease COVID-19, and continue till today. As of March 23, 2021, the outbreak has infected 124,313,054 worldwide with a total death of 2,735,707. The use of traditional medicines as an adjuvant therapy with western drugs can lower the fatality rate due to the COVID-19. Therefore, in silico molecular docking study was performed to search potential phytochemicals and drugs that can block the entry of SARS-CoV-2 into host cells by inhibiting the proteolytic cleavage activity of furin and TMPRSS2.

**Experimental procedure:** The protein-protein docking of the host proteases furin and TMPRSS2 was carried out with the virus spike (S) protein to examine the conformational details and residues involved in the complex formation. Subsequently, a library of 163 ligands containing phytochemicals and drugs was virtually screened to propose potential hits that can inhibit the proteolytic cleavage activity of furin and TMPRSS2.

**Results and conclusion:** The phytochemicals like limonin, gedunin, eribulin, pedunculagin, limonin glycoside and betunilic acid bind at the active site of both furin and TMPRSS2. Limonin and gedunin found mainly in the citrus fruits and neem showed the highest binding energy at the active site of furin and TMPRSS2, respectively. The polyphenols found in green tea can also be useful in suppressing the furin activity. Among the drugs, the drug nafamostat may be more beneficial than the camostat in suppressing the activity of TMPRSS2.

© 2021 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh human coronavirus is highly contagious that caused the disease COVID-19.1 After the first infected person identified from Wuhan, China in December 2019, the virus SARS-CoV-2 outbreak worldwide and infected 124,313,054 with a total death of 2,735,707 as of March 23rd 2021. The viral strain of SARS-CoV-2 belongs to beta coronavirus and suspected of zoonotic transfer via bat to human beings. The research study revealed that the pangolin-CoV and batCoV RaTG13 are closely related to SARS-CoV-2, and expected to be the proximal source of SARS-CoV-2.2 It is important to mention here that there are no recommended therapeutics available against the known human coronaviruses, i.e., the two highly pathogenicity coronaviruses (SARS-CoV, MERS-CoV outbreak in 2002 and 2012 respectively), and the other four pathogenic coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 outbreak in 1966, 1967, 2004 and 2005, respectively).3 Also, there was no recommended therapeutics available at the beginning of the spread of SARS-CoV-2, which triggered exponential growth in research from the beginning of the year 2020 to understand the morphology, genomic sequence and virus-host cell interactions of SARS-CoV-2 to formulate suitable therapeutic approaches to fight against COVID-19.4–6

SARS-CoV-2, the enveloped and spherical-shaped virion with an approximate diameter of 120 nm contains a positive-sense ssRNA genome of about 30000 bp. The genome encodes with four important...
structural proteins (nucleocapsid, membrane, envelope and spike), around sixteen non-structural proteins (NSP1-16) and some accessory proteins. The trimeric spike (S) glycoprotein protruding from the SARS-CoV-2 envelope plays the key role in viral infection, where the S1 subunit initiates the virus-receptor binding by interacting with the human host cell receptor angiotensin-converting enzyme 2 (ACE2), and the S2 subunit play the role in viral fusion into the target cell. The S1 subunit possesses two key domains, i.e., N-terminal domain (NTD) and C-terminal domain (CTD). The CTD of SARS-CoV-2 contains the receptor-binding domain (RBD) that interacts with human ACE2 (Fig. 1). Following the interaction of SARS-CoV-2 virus with the human ACE2 receptor, the host proteases like furin and TMPRSS2 play the pivotal role to activate the S protein that allows the fusion of viral genome into the target cell.

The human furin enzyme cleaves a specific section to convert the synthesized proteins to biologically active form. It is also called as PACE (paired basic amino acid cleaving enzyme) and subtilisin-like peptidase. It is a calcium dependent serine endoprotease that cleaves the processing sites of the precursor protein. Furin cleaves polyprotein precursor HIV envelope such as gp41 and gp20 involved in virus host entry. Similarly, it also involved in some viral proteins preprocessing such as influenza, Ebola, dengue fever, Marburg virus, Pseudomonas exotoxin, papillomavirus, anthrax toxin and SARS-CoV-2 etc. Furin cleaves S1 (SPRARRYS) site of SARS-CoV-2, direct emergence in spike glycoprotein activation for viral entry into the host system. It is a potent cleavage site known as the polybasic cleavage site or multibasic site of SARS-CoV-2. In addition, the spike glycoprotein S1/S2 site of SARS-CoV-2 is cleaved by the transmembrane protease serine 2 (TMPRSS2), which played a predominant role in enhancing the spike glycoprotein activity. TMPRSS2 activates the SARS-CoV and SARS-CoV-2 spike glycoprotein though N-terminal and C-terminal cleavage sites, and priming the S protein for virus endocytosis. TMPRSS2 also activates human metapneumovirus and influenza virus hemagglutinin entry into the host cells. TMPRSS2 cleaves the S protein in the lungs of SARS-CoV-2 infected person and promotes the pathogenicity. Therefore, the TMPRSS2 serine protease opted as an important therapeutic target. In short, SARS-CoV-2 S protein S1 site is cleaved by furin, and subsequently, TMPRSS2 mediates the S2 site cleavage and activation of S protein upon interactions with S1/ S2 site residues ARG683, ARG685, SER686, ARG815 and SER816 (Fig. 1).15,26

In this manuscript, the protein-protein docking studies were performed to investigate the binding and conformational details of the complexes formed between the proteases furin and TMPRSS2 with the SARS-CoV-2 S protein. In addition, the human proteases furin and TMPRSS2 active sites were targeted to identify potential ligands through molecular docking analyses that can inhibit the functions of furin and TMPRSS2 during the disease establishment. Molecular docking is a useful computational approach to screen potential ligands from various databases/libraries, which saves both the experimental time and cost in the field of drug discovery. Molecular docking not only predicts the binding affinity or strength of association of the ligand at the active site of target protein but also the mode of interactions. As a part of our ongoing in silico computational research to search potential inhibitors for SARS-CoV-2, a library of 163 ligands was created by collecting the best phytochemicals from triterpenoids and polyphenols that cleared the limitations of ADMET/drug-likeliness from our recently reported work,18,19 the terpenoids based synthetic compounds/phytochemicals available in the drugbank, and also the drugs that are known for their activity against furin and TMPRSS2.20–23 The library also consists of several important triterpenoids and polyphenols known for their antiviral activity against SARS-CoV whose protein content is almost 80% similar to SARS-CoV-2.24 These ligands were docked with the proteases (furin and TMPRSS2), and the protein-ligand interaction study was performed to identify the potential ligands that bind at the active sites with high binding energy.

![Fig. 1. Active sites of furin and TMPRSS2 involved in S1/S2 site cleavage activity of spike protein. The furin catalytic residues are ASP153, HIS194, ASN295 and SER368. For TMPRSS2, the catalytic sites are HIS296, ILE346 and SER441, whereas the substrate binding sites are ASP435, ASP435, SER460, SER465 and LYS467.](image-url)
2. Computational methods

2.1. Proteins and ligand preparations

The proteins 3D structures were retrieved from the PDB database (www.rcsb.org). The crystallography structures of the spike protein of SARS-CoV-2 (PDB ID: 6ZGH), ACE2 (PDB ID: 6M17), furin (PDB ID: 5JXH) and TMPRSS2 (PDB ID: 128G, 6KSD, 3TN2 and 5CE1) were modelled using Modeller version 10.0. The modelling of TMPPRSS2 was performed with five template structures obtained from PDB ID: 128G, 6KSD, 3TN2 and 5CE1, and the best model having the least discrete optimized protein energy (DOPE) score – 29028.181641 was selected for further in silico computational studies. The missing residues and atoms of the protein were reconstructed using SWISS-PdbViewer 4.1.0. The modelled proteins were validated using PD8sum online tool. The structures of the 163 ligands were retrieved from EMBL-EBI (www.ebi.ac.uk/chebi/advancedSearchFT.do), PUBCHEM (https://pubchem.ncbi.nlm.nih.gov/) or drugbank (https://www.drugbank.ca/). The collected information,27 where \( E_{\text{attr}} \) and \( E_{\text{rep}} \) denote the attractive and repulsive contributions to the van der Waals interaction energy \( E_{\text{vdw}} \), \( E_{\text{elec}} \) is an electrostatic energy term, and \( E_{\text{pair}} \) represents the desolvation contributions. \( E_{\text{pair}} \) has been parameterized on a set of complexes that included a substantial number of enzyme inhibitor pairs and multi-subunit proteins, and therefore the resulting potential assumes good shape and electrostatic complementarity. The coefficients \( w_1 \), \( w_2 \), and \( w_3 \) specify the weights of the corresponding terms, and are optimally selected for different types of docking problems. The protein–protein interactions were visualized by using the BioVia discovery studio.28

2.2. Protein-protein docking

The protein-protein molecular docking was performed through ClusPro online docking server (https://cluspro.bu.edu/queue.php).26 This server generates 25 protein-protein docking models binding with multiple conformations and calculates the weighted energies with the scoring function \( E = E_{\text{attr}} + w_1E_{\text{rep}} + w_2E_{\text{elec}} + w_3E_{\text{pair}} \) for every binding conformation,27 where \( E_{\text{attr}} \) and \( E_{\text{rep}} \) denote the attractive and repulsive contributions to the van der Waals interaction energy \( E_{\text{vdw}} \); \( E_{\text{elec}} \) is an electrostatic energy term, and \( E_{\text{pair}} \) represents the desolvation contributions. \( E_{\text{pair}} \) has been parameterized on a set of complexes that included a substantial number of enzyme inhibitor pairs and multi-subunit proteins, and therefore the resulting potential assumes good shape and electrostatic complementarity. The coefficients \( w_1 \), \( w_2 \), and \( w_3 \) specify the weights of the corresponding terms, and are optimally selected for different types of docking problems. The protein–protein interactions were visualized by using the BioVia discovery studio.28

2.3. Protein-ligand docking

The protein-ligand molecular docking was performed by AutoDock Vina 1.1.2 software29 to estimate the binding energies of the ligands towards the protein targets furin and TMPPRSS2. The protein and the ligand structures were prepared using MGL 1.5.6, and the grid files were generated that covers all the substrate binding sites and active sites. The molecular docking were performed by applying the Lamarckian genetic algorithm (LGA). The docking output files were analyzed by using the BioVia discovery studio and Ligplot plus.30,31

3. Results and discussion

3.1. Protein-protein docking

The interaction of the spike glycoprotein of SARS-CoV-2 with human ACE2 receptor initiates the virus–receptor binding followed by the host proteases (furin and TMPPRSS2) activate the spike protein that allows the fusion of viral genome into the target cell. The protein-protein docking between spike glycoprotein with ACE2 in ClusPro lower the energy by –908.4 kJ/mol due to multiple non-covalent interactions between the two proteins (Fig. S1). The interaction of spike glycoprotein with ACE2 is studied, and their active sites are targeted extensively to propose potential phytochemicals and drugs compared to the proteases furin and TMPPRSS2.32–35 Therefore, the binding and conformational details of the proteases furin and TMPPRSS2 were examined by performing the in silico protein–protein docking studies. Among the 25 generated models, the best pose of the proteases furin and TMPPRSS2 binding at the active sites (substrate binding site and/or catalytic site) of S protein is shown in Fig. 2. The furin binds firmly with S protein PRRAR|S site, whereas the TMPPRSS2 at the active residues present in both S1 and S2 domains.

The protein–protein docking of furin and S protein from Cluspro server resulted the binding of furin at the cleavable site with the lowest energy –1026.8 kJ/mol. Furin binding to SARS-CoV-2 S1 site and cleavable PRRAR|S residues with the amino acid residues ALA267, PRO266, LYS261, ASP264, GLY265, TYR308, PRO256, GLY255, VAL231, SER253, MET226, LEU227, ASP153, ASP154, ASP228, HIS194, ARG185, ASP191, and ASP228.

TMPPRSS2 docked with S protein predicted 25 binding conformations, and the model binding at the active site of S1/S2 was selected that showed the lowest energy –886.7 kJ/mol (Fig. 4). TMPPRSS2 cleaved the spike protein at two different sites, i.e. ARG815/SER816 and ARG682/SER686. Accordingly, the protein–protein docked structure was analyzed and the important non-covalent interactions of TMPPRSS2 at the cleavage of S protein is shown in Fig. 4. The S2 domain residue SER810 forming conventional hydrogen bond with ARG413. The residues GLY259 and THR387 pose conventional hydrogen bonds with ARG683 of PRRAR site. GLU388 forming charge-charge and carbon hydrogen bond with ARG685, and also pose a bump with the ALA684 residue of the S protein. The residue ARG683 of S protein is interacting with GLY259, THR387 by conventional hydrogen bond, whereas ARG685 posing carbon hydrogen bond and charge-charge interaction with GLU388. The substrate binding and the catalytic sites residues such as HIS296, ILE346, SER441, ASP435, SER460, GLY462, LYS467 and ASN465 plays a critical role in proteolytic cleavage, and therefore, these possible binding conformations between TMPPRSS2 and S protein at S1/S2 sites leads to cleavage activity.

3.2. Docking with furin

The protease furin is a proprotein that activates protein functions and converts into a biologically active form by cleaving some part of the protein. It also cleaves the S protein of the SARS-CoV-2 virus, and promotes the S protein to bind with TMPPRSS2 that activates the process of endocytosis. The S protein residues ASN657 and GLN690 are the prime interacting amino acids with 105 residues of the furin protease pose multiple non-covalent interactions to cleave the S protein residues, and concomitantly activates S protein to bind with TMPPRSS2. During the cleavage of S protein, the residues ASP153, HIS194, ASN295 and SER368 of furin play the important role in catalytic activity. Therefore, the molecular docking of 163 ligands were performed by adjusting the grid dimensions
localizing the active site at the centers $x: 34.6056$, $y: 37.5109$, $z: 3.3422$. After docking, the protein-ligand interaction study was performed to identify the ligands that bind with the catalytically active residues of furin. Total 23 ligands bind with the catalytic residues of furin at the active site with the dock score in the range $-8.7$ to $-7.0$ kcal/mol (Table S1). The dock score supported the effective binding of the ligands at the active site of furin, and also comparably higher than the well-known furin inhibitor...

Fig. 2. Protein-protein docked structure of (a) furin and (b) TMPRSS2 with S protein demonstrates the primary contacts at the proteolytic sites of S protein.

Fig. 3. Representing the furin interactions with S protein cleavage site, with possible binding conformations of furin residues VAL231, GLY265, TYR308 binding affinity to S1 ARG683, ARG682 sites to cleave the PRRAR/S residues.
decanoyl-RVKR-chloromethylketone (CMK) binding with dock score $-6.1$ kcal/mol (Fig. S2).19 Based on the reported medicinal properties and dock score at the active site of furin, twelve best ligands (Fig. S3) were identified and summarized in Table 1.

Limonin, the triterpenoid based phytochemical is the first isolated limonoids found mainly in the citrus fruit is known for inhibiting colon cancer cell proliferation through apoptosis and antiviral against HIV-1 and HTLV-1 replication.50 Limonin was proposed as potential phytochemicals that bind at the active site of the main protease Mpro and RdRp of SARS-CoV-2 with the dock score $-8.7$ and $-8.2$ kcal/mol, respectively.18 The present study also revealed that limonin is binding at the active site of furin with a higher dock score of $-8.7$ kcal/mol. Limonin is forming multiple interactions with the residues like ASN295, ARG298, GLU299, THR365, ASP259, ASP258, TRP328, and GLY296 (Fig. 5a). Similarly, eribulin, an anti-cancerous agent exhibiting strong affinity towards active site showing multiple interactions with the residues ASN295, ARG193, ASP259, HIS194, SER368, ARG197 with the binding energy of $-8.6$ kcal/mol. Pedunculagin also an anti-cancerous agent and carbonic anhydrase inhibitor found in the pericarp of pomegranate posing at the active site of furin and binding to ASN295, HIS194, ASP258, GLU299, GLY296, TRP328 residues with the conventional hydrogen bond and non-covalent interactions with the SER368, ARG193 residues.51 The binding of the best pose of the ligands limonin, pendunculagin and eribulin at the active site of furin is shown in Fig. 5b.

### Table 1

| Compounds      | B.E. | Residues interacting at active site                                                                 | Medicinal importance                                                                                   | Ref.   |
|----------------|------|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--------|
| Limonin        | $-8.7$ | ASN295, ARG298, GLU299, THR365, ASP259, ASP258, TRP328, GLY296.                                      | Anti-viral properties, Inhibiting HIV-I, HTLV-I replication, and inhibiting proliferation of colon cancer cell. | 36,37   |
| Eribulin       | $-8.6$ | ASN295, ASP191, ASN190, ARG193, ASP259, HIS194, SER368, ARG197.                                       | Anticancer agent, treats breast cancer and liposarcoma.                                                 | 38     |
| Pedunculagin   | $-8.5$ | ASN295, HIS194, ASP258, GLU299, GLY296, TRP328, SER368, ARG193.                                      | Carbonic anhydrase inhibitor, anti-human myelogenous leukemia.                                         | 39,40   |
| Maytansine     | $-8.4$ | HIS194, ASN295, TRP328, THR365, HIS364, ARG193, ASP191.                                               | Cytotoxic agent, microtubules inhibitor.                                                               | 41     |
| Bevirimat      | $-8.1$ | HIS194, ASN295, TRP328, THR365, HIS364, ARG193, ASP259, HIS194, SER368, ARG193, ASP191.              | HIV gap protein inhibitor in development of maturation, protease inhibitor.                           | 42,43   |
| Ellagic Acid   | $-8.0$ | HIS194, SER368, ASN295, THR365, HIS364, ARG197, ARG193, ASP191.                                      | Antioxidant agent.                                                                                    |        |
| Glycyrrhetinic acid | $-8.0$ | HIS194, SER368, THR365, HIS364, ASN295, TRP328, ASP258, ARG193.                                      | Suppressed NF-$\kappa$B activation in TNF-$\alpha$-induced hepatocytes                                 | 44     |
| Gedunin        | $-7.8$ | ASN295, THR365, ARG298, GLU299, GLY296, ASP259.                                                      | Hsp90 inhibitor, Under investigation as anti-cancer agent and antimalarial activity.                  | 45,46   |
| Limonin glucoside | $-7.8$ | ASN295, TRP328, SER368, ASP258, HIS194, ARG193, ARG197.                                              | Decreases liver enzymes expression associated with chronic inflammatory disease.                    |        |
| Epigallocatechin | $-7.7$ | HIS194, ASP191, HIS364, SER368, ASN295, MET189, ARG193, ASN190.                                      | Potential nutraceutical agent.                                                                        | 47     |
| Betulinic acid | $-7.2$ | ASN295, HIS194, TRP328, GLY366, ASP259, ARG298, GLU299, SER368.                                      | Potential agent against cancer and HIV infection.                                                     | 48     |
| Epicatechin    | $-7.1$ | HIS194, SER368, ASP191, HIS364, THR365, MET189, ARG193, ASN190, ARG197.                            | Antioxidant.                                                                                         | 49     |

Fig. 4. Representing the TMPRSS2 interactions with S protein cleavage site with possible binding conformations at S1/S2 site ARG683, ALA684, ARG685 and SER810.
The phenolic phytochemicals like ellagic acid, epigallocatechin, epicatechin also bound to the active site and inhibiting the furin activity through binding with HIS194, ARG193, ARG197, ASP191, ASN295, THR364, MET189 and THR365 residues posing π-sigma, π-anion and conventional hydrogen bonds. Ellagic acid is a well-known antioxidant that not only inhibiting furin\textsuperscript{52} and also inhibiting ACE2 active site with a better binding affinity.\textsuperscript{19} Epi-
catechin and epigallocatechin found in green tea leaves have a predominant role as antioxidant and antiviral properties. Several limonoids and triterpenoids based ligands like 17-
hydroxyazadiradione, gedunin, azadiradione, glycyrrhitinic acid and limoninglucoside showed binding affinity towards HIS194, SER368, ASN295 residues and also interacting with TRP328, HIS300, ALA332, ALA326, ALA517 with covalent interactions and ASN407, ALA408, ASN409, ASN325, PRO327, SER330, GLY297, GLU331, SER302, ASP301 posing non-covalent interactions of the substrate binding site. Glycyrrhitinic acid commonly known as enoxolone reported for potential activity against peptic ulcers.\textsuperscript{53} The enoxolone structure poses pharmacological properties that may exhibit antiviral, antibacterial and anti-cancerous properties.\textsuperscript{54} Importantly, enoxole is the hydrolysis product of glycyrrhizic acid found in the herb licorice, and the glycyrrhizic acid is claimed to be an important phytochemical against SARS-CoV-2.\textsuperscript{18} Limonin glucoside inhibiting the colon adenocarcinoma cells and 17-

Fig. 5. (a) Ligplot of limonin pose at the active site of furin, and (b) the surface image of furin active site docked with limonin, pendunculagin and eribulin.
hydroxyazadiradione known for antifungal activity. In addition, the betulinic acid-like compound bevirimat well known for anti-HIV activity binds effectively at the active site of furin.

3.3. Docking with TMPRSS2

TMPRSS2 is a serine protease that activates the SARS-CoV and SARS-CoV-2 S protein through N-terminal and C-terminal cleavage sites. TMPRSS2 cleaves the S protein in the lungs of SARS-CoV-2 infected person and promotes pathogenicity. SARS-CoV-2 S protein S1/S2 cleaved by furin, and subsequently, TMPRSS2 mediates the cleavage and activation of the S protein. TMPRSS2 cleaved the S protein at two potential sites, i.e., N-terminal (ARG685, SER686) and C terminal (ARG815, SER816). So, the TMPRSS2 serine protease opted as a potential therapeutic target. The TMPRSS2 possesses catalytically active residues HIS296, ILE346 and SER441, and the substrate binding residues ASP345, ASP435, SER460, SER465 and LYS467. For virtual screening of potential compounds, the structurally refined TMPRSS2 protein was used for molecular docking with 163 ligands by adjusting the grid dimensions x: 1.6407, y: 2.5071, z: 40.3205 that covered the entire substrate binding and catalytic sites. The protein-ligand interaction study revealed that total 90 ligands bind with the catalytic/substrate binding residues of TMPRSS2 at the active site and their dock score observed between \(-8.7\) and \(-5.0\) kcal/mol (Table S1). It is important to mention here that the approved drug nafamostat (\(-8.1\) kcal/mol) binds at the active site of TMPRSS2 with a higher binding affinity than the drug camostat (\(-6.6\) kcal/mol), and their best pose at the active site of TMPRSS2 is shown in Fig. 6. Based on the computational results, the use of nafamostat is expected to be more beneficial than the camostat.\(^{20}\) Also, the nafamostat binds more efficiently at the active site of TMPRSS2 compared to the protease inhibitors aloxistatin (\(-5.2\) kcal/mol) and nelfinavir (\(-7.0\) kcal/mol).\(^{21,23}\) Therefore, considering nafamostat as control, fourteen best dock score ligands were selected (Fig. S3) and their interactions at the active site of TMPRSS2 along with medicinal properties are summarized in Table 2.

The phytochemicals such as gedunin, deoxyabacunone, 2-hydroxyseneganolide, 7-deacetyl-7-benzoylgedin and 7-deacetylgeduin proven to be antiviral agents were actively binding at the catalytic site of TMPRSS2. Gedunin is extracted mainly from the neem (azadirachtaindica) is computationally proposed as a potential phytochemical, and binds firmly at the active site of receptor-binding domain of S protein and ACE2.\(^{18}\) Gedunin is also binding firmly at the active site of TMPRSS2 by forming non-covalent interactions with the residues HIS296, CYS465, GLY462, SER460, SER441, GLY464, CYS437 and CYS297 (Fig. 7a). The binding of the three best phytochemicals gedunin, deoxyabacunone and 2-hydroxyseneganolide at the active site of TMPRSS2 is shown in Fig. 7b.

Limonin and limonin glucoside derivative known for antiviral and anti-cancerous properties can also potentially inhibit the TMPRSS2 activity by interacting with the residues LYS342, GLN438 by forming a conventional hydrogen bond, and \(\pi\)-alkyl and \(\pi\)-\(\pi\) interactions with CY465, HIS296 and CYS437, TRP461. The catalytic residue SER441 posing non-covalent interaction with limonin. Betulinic acid and bevirimat are also showed potential to inhibit serine protease-2 activity, and these compounds may be potential to use against SARS-CoV-2 because of their anti-HIV properties.

4. Conclusions

In summary, the binding and conformational details of the proteases furin and TMPRSS2 with the S protein of SARS-CoV-2 was examined in silico by performing protein-protein docking, and the residues involved in catalytic or substrate binding activity were discussed. Furin showed lower Cluspro energy than TMPRSS2 in binding with S protein, and the role of furin may be investigated in details to search potential vaccines or drugs against the COVID-19. Virtual screening of 163 ligands by performing protein-ligand docking by targeting the active site of furin and TMPRSS2...
resulted several key compounds that can suppress the proteolytic activity. Limonin and gedunin found mainly in the citrus fruits and neem showed the higher binding energy at the active site of furin and TMPRSS2, respectively among all the examined compounds. The compounds like limonin, eribulin, pedunculagin, gedunin, limonin glycoside and betulilic acid bind at the active sites of both furin and TMPRSS2. The polyphenols found in green tea can also be useful in suppressing the furin activity. For TMPRSS2, the approved drug nafamostat may be more beneficial than the camostat. The effective binding of glycyrrhetinic acid and baicalein with the proteases, along with their effective binding to the proteins target associated with SARS-CoV-2 makes them the potent phytochemicals similar to limonin and gedunin for formulating traditional medicines. Overall, the current in silico outcomes will be useful in selecting the key targets for further experimental studies that can be beneficial against COVID–19 by inhibiting the proteolytic activity of the proteases furin and TMPRSS2.

### Table 2

Compounds pose at the TMPRSS2 active site with their binding energy (B.E., kcal/mol) and medicinal properties.

| Compounds             | B.E. | Residues interacting at active site | Medicinal and biological properties                                                                 |
|-----------------------|------|-------------------------------------|-------------------------------------------------------------------------------------------------------|
| Gedunin               | –8.7 | HIS296, GYS465, GLY462, SER460, SER441, GLY464, CY3437, GYS297. | Hsp90 inhibitor, Under investigation as anti-cancer agent and antimalarial activity.                 |
| Deoxyobacunone        | –8.4 | HIS296, GYS465, GLY464, GLY462, GYS297, SER441, SER460. | Stimulatory activity in *strigahermotheca* seeds                                                     |
| 2-hydroxyseneganolide | –8.4 | HIS296, TRP461, SER460, SER463, GLY462, LYS432, THR341, GYS464. | Anti-fungal.                                                                                         |
| Pedunculagin          | –8.4 | SER441, HIS296, GYS438, GLY464, GLY462, GYS297, SER436. | Carbonic anhydrase inhibitor, anti-human myelogenous leukemia.                                       |
| 7-deacetyl-7-benzylgedunin | –8.3 | HIS296, GYS465, SER436, SER441, SER460, TRP461, GLY462, SER436. | Cytotoxic activity against HL60 leukemia cells and antineoplastc agent.                             |
| 7-deacetylgedunin      | –8.3 | HIS296, GYS465, GYS437, SER436, GYS437, GYS438, GYS462, SER441, SER460, TRP461, GLY462. | Activates Keap1/Nrf2/HO-1 signaling and suppress inflammatory response.                           |
| Limonin               | –8.3 | HIS296, SER441, LYS342, TRP461, GYS437, GYS465, GLY462, GLY464. | Anti-viral properties, Inhibiting HIV-1, HTLV-1 replication, and inhibiting proliferation of colon cancer cell. |
| Solamargin            | –8.3 | HIS296, SER441, GYS438, GLU499, LEU419, TRP461, GLY439. | Anti-inflammatory and anti-proliferative agent.                                                     |
| Betulinal acid         | –8.3 | SER460, SER441, HIS296, LYS432, VAL280, LEU302, GYS438. | Anti-angiogenic, anti-retroviral and anti-inflammatory agent.                                      |
| Eribulin              | –8.2 | SER441, LYS340, GYS438, LYS342, HIS296, SER460, LYS342. | Anticancer agent, treats breast cancer and liposarcoma.                                            |
| Biaicalein            | –8.2 | HIS296, LYS438, GLY464, LYS342, TRP461, LEU419, SER441, SER460. | Anti-inflammatory and anti-proliferative agent.                                                   |
| Limonin glucoside     | –8.1 | GLY464, GLY462, HIS296, LYS342, TRP461, GLY439, SER441, SER460. | Decreases liver enzymes expression associated with chronic inflammatory disease.                 |
| Nafamostat            | –8.1 | HIS296, SER436, ASP345, GYS437, SER441, GYS465, GLN438, TRP461. | Serine protease inhibitor, antiviral and anti-cancerous agent.                                     |
| Hesperidin            | –8.0 | SER441, HIS296, TRP461, LYS342, GYS438, SER436, CY3437. | Antioxidant and anti-allergen.                                                                    |

Fig. 7. (a) Ligplot of gedunin posing at the active site of TMPRSS2, and (b) the surface image of TMPRSS2 active site docked with gedunin, deoxyobacunone and 2-hydroxyseneganolide.
Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Authors are thankful to Director, SVNIT for providing necessary research facilities and infrastructure.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jtcm.2021.04.001.

References

1. Abdel-Moneim AS, Abdelwhab EM. Evidence for SARS-CoV-2 infection of animal hosts. Pathogens. 2020;9(7):529. https://doi.org/10.3390/pathogens9070529.
2. Cheng YW, Chao TL, Li CL, et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020;33(2):108254. https://doi.org/10.1016/j.celrep.2020.108254.
3. Zaki A, Al-Karmalawy A, El-Amier Y, Ashour A. Molecular docking reveals the protein that harbors a high capacity to mediate membrane fusion. J Cell. 2020;367(6485):1444–1448. https://doi.org/10.1016/j.jcell.2020.02.052. e8.
4. Balestrieri E, Pizzimenti F, FerlazzoA, et al. Antiviral activity of seed extract potential inhibitors from limonoids and triterpenoids for COVID-19. J Agric Food Chem. 2020;68(19):10318–103185. https://doi.org/10.1021/acs.jafc.0c02999.
5. Ysrafi Astuni I. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407–412. https://doi.org/10.1016/j.dsx.2020.04.020.
6. Zou J, Zhang Y, Wang Z, et al. Potential inhibitors from limonoids and triterpenoids for COVID-19. Mol Cell. 2020;784. https://doi.org/10.1016/j.molcel.2020.04.022. e5.
7. Xing Y, Li X, Gao X, Dong Q. Natural polymorphisms are present in the furin cleavage site of the SARS-CoV-2 spike glycoprotein. Front Genet. 2020;11:783. https://doi.org/10.3389/fgene.2020.00783.
8. Vardhan S, Dholakiya BZ, Sahoo S. Protein-ligand Interaction Study to Identify Potential Dietary Compounds Binding at the Active Site of Therapeutic Target Proteins of SARS-CoV-2. arXiv:2005.11776vol. 1.
9. Abdel-Moneim AS, Hana RK, Al-Arabi I, et al. Identification of a second human subtilisin-like protease gene in the fes/lps region of chromosome 15. DNA Cell Biol. 1991;10(10):757–769. https://doi.org/10.1089/10981991.1991.10.757.
10. Checkley M, Lutrigge B, Freed E. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol. 2011;411(4):582–608. https://doi.org/10.1016/j.jmb.2011.04.042.
11. Coutard B, Valle C, de Lamballerie C, Canard B, Seidah NG, Decroly E. The spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;79(2):2746–2759. https://doi.org/10.1016/j.molcel.2020.02.018.
12. Vardhan S, Dholakiya BZ, Sahoo S. Potential inhibitors from limonoids and triterpenoids for COVID-19. Comput Biol Med. 2020;124:103936. https://doi.org/10.1016/j.compbiomed.2020.103936.
13. Elmaaty AA, Alnajjar R, Hamed MIA, Khattab M, Khalifa MM, Al-Karmalawy AA. TMPRSS2 block SARS-CoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J Med Virol. 2020;92(10):2087–2095. https://doi.org/10.1002/jmv.25855.
14. Smith P, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic and immunologic effects of 10 mg of 17-AAG with subcutaneous 25 mg of pegylated liposomal doxorubicin (Doxil) in patients with advanced solid tumors. J Clin Oncol. 2011;29(16):2159–2166. https://doi.org/10.1200/JCO.2010.32.8495.
15. Vardhan S, Dholakiya BZ, Sahoo S. Protein-ligand Interaction Study to Identify Potential Dietary Compounds Binding at the Active Site of Therapeutic Target Proteins of SARS-CoV-2. arXiv:2005.11776vol. 1.
16. Weissenstein A. TMPRSS2-Inhibitors play a role in cell entry mechanism of COVID-19: an insight into camostat and nafamostat. J Regen Biol Med. 2020;22(2):1–3. https://doi.org/10.3731/jasmp.2020.22.2.022.
17. Bhattacharya C, Bhattacharjee A, Saha A, et al. A computational study of the Cricetulus griseus carboxypeptidase A2 protein structure. Arch Pharm Res (Seoul). 2020;124, 103936. https://doi.org/10.1002/jmv.25855.
18. Smith P, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic and immunologic effects of 10 mg of 17-AAG with subcutaneous 25 mg of pegylated liposomal doxorubicin (Doxil) in patients with advanced solid tumors. J Clin Oncol. 2011;29(16):2159–2166. https://doi.org/10.1200/JCO.2010.32.8495.
43. Priyadarssini K, Khopde S, Kumar S, Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem. 2002;50(7):2200–2206. https://doi.org/10.1021/jf011275g.

44. Chen H, Kang S, Lee I, Lin Y. Glycyrrhetinic acid suppressed NF-κB activation in TNF-α-induced hepatocytes. J Agric Food Chem. 2014;62(3):618–625. https://doi.org/10.1021/jf405352g.

45. Brandt G, Schmidt M, Prisinzano T, Blagg B. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary Structure–Activity relationships. J Med Chem. 2008;51(20):6495–6502. https://doi.org/10.1021/jm8007486.

46. Kelley D, Adkins Y, Zunino S, et al. Citrus limonin supplementation decreased biomarkers of liver disease and inflammation in overweight human adults. J Funct Foods. 2015;12:271–281. https://doi.org/10.1016/j.jff.2014.11.026.

47. Zhu N, Huang T, Yu Y, LaVeie E, Yang C, Ho C. Identiﬁcation of oxidation products of (-)-EpigallocatechinGallate and (-)-Epicatechin with H2O2. J Agric Food Chem. 2000;48(4):979–981. https://doi.org/10.1021/jf991188c.

48. Cichewicz R, Kouzi S. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev. 2003;23(1):50–114. https://doi.org/10.1002/med.10053.

49. Harada M, Kan Y, Naoki H, et al. Identiﬁcation of the major antioxidative metabolites in biological ﬂuids of the rat with ingested (-)-Catechin and (-)-Epicatechin. BioSci Biotechnol Biochem. 1999;63(6):973–977. https://doi.org/10.1271/bbb.63.973.

50. Chidambara Murthy K, Jayaprakash G, Kumar V, Rathore K, Patil B. Citrus limonin and its glucoside inhibit colon adenocarcinoma cell proliferation and AR-coactivators interaction. J Med Chem. 2011;54(6):2314–2323. https://doi.org/10.1021/jm100785g.

51. Rahimi HR, Arastoo M, Ostad SN. A comprehensive review of punicagranatum (pomegranate) properties in toxicological, pharmacological, cellular and molecular biology researches. Iran J Pharm Res (IJPR). 2012;11(2):385–400.

52. Brusselmann K, Schrijver ED, Heyns W, Verhoeven JW. Epigallocatechin–3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Canc. 2003;106(6):856–862. https://doi.org/10.1002/ijc.11317.

53. Murray M. Glycyrrhizaglabra (licorice). Textbook of Natural Med. 2020: 641–647. https://doi.org/10.1016/b978-0-323-43044-9.00085-6. e3.

54. Roohbakhsh A, Iranshahy M, Iranshahi M. Glycyrrhetinic acid and its derivatives: anti-cancer and cancer chemopreventive properties, mechanisms of action and structure–cytotoxic activity relationship. Curr Med Chem. 2016;23(5):498–517. https://doi.org/10.2174/0929867323666160112122256.

55. Rugutt J, Rugutt K, Berner D. Limonoids from Nigeriantarassonioiabyssinicacid their stimulatory activity againstStrigaaberomonticaSeeds. J Nut Prod. 2001;64(11):1434–1438. https://doi.org/10.1016/j.nut.2001.0100183.

56. Abdelgalel S, Iwagawa T, Doe M, Nakatani M. Antiﬁungal limonoids from the fruits of Khayaacネンデガネンジ. Fitoterapia. 2004;75(6):566–572. https://doi.org/10.1016/j.fitote.2004.06.001.

57. Kikuchi T, Ishii K, Noto T, et al. Cytotoxic and apoptosis-inducing activities of limonoids from the seeds ofAçaιirachidantzaic(a.neem). J Nut Prod. 2011;74(4):866–870. https://doi.org/10.1021/jf104498p.

58. Chen J, Zhu G, Su X, et al. 7-deacetylgedunin suppresses inﬂammation in overweight human adults. J Funct Foods. 2018;49:281. https://doi.org/10.1016/j.jff.2018.03.001.

59. Fatwardhan R, Sharma D., et alSandur S. Baicalein exhibits anti-inﬂammatory effects via inhibition of NF-κB transactivation. Biochem Pharmacol. 2016;108:75–89. https://doi.org/10.1016/j.bcp.2016.03.013.

60. Hoffmann M, Schroeder S, Kleine-Weber H, Muller M, Drosten C, Pohlmann S. NafamostatMesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64(6). https://doi.org/10.1128/AAC.00754-20.

61. Parhi H, Roobakhsh A, Soltani F, Rezaee R, Iranshahi M. Antioxidant and antiinflammatory properties of the citrus ﬂavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res. 2014;28(3):323–331. https://doi.org/10.1002/ptr.5256.

62. Xu D, Chen Q, Liu Y, Wen X. Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR-N-C dimerization and AR-coactivators interaction. Oncotarget. 2017(8):105561–105573.